Navigation Links
Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational Pan-HER Inhibitor; Closes $55 Million Private Placement and Completes Merger
Date:10/5/2011

LOS ANGELES, Oct. 5, 2011 /PRNewswire/ -- Puma Biotechnology, Inc., a development stage biopharmaceutical company, today announced an agreement with Pfizer to license the worldwide commercial rights to neratinib, a potent, irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, ErbB1 (EGFR), ErbB2 (HER2) and ErbB4 (HER4) kinases.  Neratinib is being studied in the neoadjuvant, adjuvant and metastatic settings in patients with HER2/ErbB2 positive breast cancer.

Under the terms of the agreement, Puma will assume sole responsibility of global product development and commercialization of neratinib.  Pfizer will be entitled to receive payments upon Puma's achievement of certain development milestones of neratinib, as well as royalty payments for any sales of neratinib.

Puma intends to focus the development of neratinib on the treatment of patients with HER2-positive locally advanced or metastatic breast cancer who have received prior trastuzumab-based therapy.  Neratinib has previously been tested in numerous clinical trials both as single agent and in combination with other anticancer drugs in this patient population.  In these studies, neratinib demonstrated substantial clinical activity and was well tolerated.  Based on the results of these studies, Puma intends to initiate clinical trials in this patient population in the first half of 2012.

Prior to the licensing agreement with Puma, Pfizer had been sponsoring two clinical trials of neratinib: 1) the NEfERTT trial, a Phase II randomized trial of neratinib in combination with paclitaxel versus trastuzumab in combination with paclitaxel for the treatment of patients who have not received previous treatment for HER2-positive metastatic breast cancer, and 2) the ExteNET trial, a Phase III study investigating the effects of neratinib after adjuvant trastuzumab in patients with early stage breast cancer.  Co
'/>"/>

SOURCE Puma Biotechnology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
2. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
3. Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement
4. Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
5. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
6. Genetic Engineering & Biotechnology News Reports on the Growing Role of Ion-Channel Studies in Global Biotech R&D
7. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
8. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
9. Dr. Ari Kiev to be Featured Speaker at Biotechnology Conference Wall Street Unplugged: The Trout Group Investor Seminar in New York July 30
10. Generex Biotechnology Corporation Initiation Coverage Review Issued By Scimitar Equity, LLC
11. Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... , Oct. 2, 2014   Mast Therapeutics, ... announced today that Edwin L. Parsley , D.O. ... and Senior Vice President.  Dr. Parsley has ... Aires Pharmaceuticals, Inc. in February 2014.  He has served ... and as Chief Medical Officer of Aires since April ...
(Date:10/2/2014)...   Intarcia Therapeutics, Inc. today announced successful ... clinical trials for ITCA 650 (exenatide, delivered continuously once ... The first trial, FREEDOM-1, was a placebo-controlled, double-blind phase ... of ITCA 650 in patients with type 2 diabetes ... significantly superior to placebo for both 40 mcg and ...
(Date:10/1/2014)...   Plexus Information Systems, Inc. (Plexus ... Systems (AIMS), announced a partnership with NextGen ... subsidiary of Quality Systems, Inc. and a leading ... Logo - http://photos.prnewswire.com/prnh/20140930/149406 ... This partnership extends the NextGen Healthcare product portfolio ...
Breaking Medicine Technology:Mast Therapeutics Announces Appointment Of Chief Medical Officer 2Mast Therapeutics Announces Appointment Of Chief Medical Officer 3Mast Therapeutics Announces Appointment Of Chief Medical Officer 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 2Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 5Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 2Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 3
... Feb. 9, 2011 Reportlinker.com announces that ... in its catalogue: Global ... Plaque Treatment 2011 ... the responses of a comprehensive survey conducted ...
... 9, 2011 Reportlinker.com announces that a new ... Asia Pacific Markets for Orthopedic ... http://www.reportlinker.com/p0377965/Asia-Pacific-Markets-for-Orthopedic-Large-Joint-Reconstructive-Devices-2011.html In 2010, the ... Japan and South Korea were valued at over ...
Cached Medicine Technology:Reportlinker Adds Global Physician Survey on Stents, Stent-Grafts and Vulnerable Plaque Treatment 2011 2Reportlinker Adds Asia Pacific Markets for Orthopedic Large Joint Reconstructive Devices 2011 2
(Date:10/2/2014)... 1, 2014 (HealthDay News) -- Genes may interact with stress ... suggests. The genetic risk occurs in about 13 percent ... finding could help these people reduce their heart disease risk ... and stress management, the Duke University researchers said. The ... found a strong link between variations in the EBF1 gene ...
(Date:10/2/2014)... By Dennis Thompson ... -- A newborn,s risk of developing celiac disease isn,t reduced ... found in wheat called gluten to an infant,s diet help ... a pair of new studies in the Oct. 2 ... put to rest hopes that a child could avoid celiac ...
(Date:10/2/2014)... Dennis Thompson HealthDay ... Forty-two states and the District of Columbia now have a ... respiratory illness that has been infecting children since the ... with the virus have died in recent weeks, but it,s ... played in those deaths, officials said. Health officials are ...
(Date:10/1/2014)... small protein beta-amyloid is strongly associated with Alzheimer,s disease; ... this peptide is the causal agent of the onset ... such confirmation is that beta-amyloid is not harmful when ... is when it self-assembles to form the so-called amyloid ... target, beta-amyloid alone, but with multiple ones because each ...
(Date:10/1/2014)... human eye, the brain of a rat and a ... says a QUT leading robotics researcher. , Dr ... the new study uses new computer algorithms to enable ... tunnels. , "This is a very Frankenstein type of ... of a thing together because we,re taking the eyes ...
Breaking Medicine News(10 mins):Health News:Genes May Make Some More Prone to Heart Disease When Under Stress 2Health News:Infant's Early Diet Doesn't Change Celiac Disease Risk, Study Finds 2Health News:Infant's Early Diet Doesn't Change Celiac Disease Risk, Study Finds 3Health News:42 States Reporting Respiratory Virus That Targets Kids 2Health News:42 States Reporting Respiratory Virus That Targets Kids 3Health News:Laying siege to beta-amyloid, the key protein in Alzheimer's disease 2Health News:Robot researcher combines nature to nurture 'superhuman' navigation 2
... LeMond ... real-to-life road feel and performance output to ensure avid cyclists and triathletes stay in ... ... introduces the all-new Revolution bike trainer that delivers the industry,s most real-to-life ...
... ... get more exposure through free publicity and other low cost PR methods. , ... (PRWEB) July 2, 2010 -- ADPublishing.org LLC, ... guide which enables small business owners to generate their own free publicity. Online PR and ...
... ... C-rich , ... IL (PRWEB) July 2, 2010 -- There’s growing consumer awareness and concern in the U.S. ... children. This month (July 2010), European food and beverage manufacturers will be required to include ...
... routine for protection against infection when percutaneous endoscopic gastrostomy ... wall, is surgically inserted in the stomach. The new ... used today. The method, presented in the British ... 200 patients at the Karolinska University Hospital in Solna, ...
... ... Northwestern Health Sciences University to create an experienced team of chiropractic and medical professionals ... years old). , ... (PRWEB) July 2, 2010 -- University of Western States has partnered with Northwestern Health ...
... ... Templar cross architecture contains math codes that support frequency-based medicine. The idea ... paradigm that will change the face of future medicine. , ... (PRWEB) July 2, 2010 -- It usually ...
Cached Medicine News:Health News:As Real as It Gets: All-New LeMond Revolution Bike Trainer Delivers Incomparable Road Feel and Performance 2Health News:As Real as It Gets: All-New LeMond Revolution Bike Trainer Delivers Incomparable Road Feel and Performance 3Health News:Publishing and Media Distribution Firm Launches Online Public Relations Kit for Businesses Seeking Free Publicity 2Health News:Surf Sweets Among Few Candy Offerings Free of Synthetic Dyes Despite Growing Consumer Concern Over Affect on Children 2Health News:Surf Sweets Among Few Candy Offerings Free of Synthetic Dyes Despite Growing Consumer Concern Over Affect on Children 3Health News:Surf Sweets Among Few Candy Offerings Free of Synthetic Dyes Despite Growing Consumer Concern Over Affect on Children 4Health News:Simpler and cheaper antibiotic prophylaxis with insertion of nutrition catheter in the stomach 2Health News:Study Seeks Effective Treatment for Adolescent Low Back Pain 2Health News:Is Frequency the Future of Medicine or an Ancient Mystery Revealed? 2Health News:Is Frequency the Future of Medicine or an Ancient Mystery Revealed? 3Health News:Is Frequency the Future of Medicine or an Ancient Mystery Revealed? 4Health News:Is Frequency the Future of Medicine or an Ancient Mystery Revealed? 5
... (ECP) is a surgical approach to glaucoma ... laser application. The ciliary body (which produces ... from the anterior or posterior segment, through ... tissues are easily and accurately identified utilizing ...
... of German Craftsmanship have produced ... the world. Ocutek® now makes ... holders of the coveted Meisterbrief ... apprenticeship, are qualified to become ...
... Craftsmanship have produced the finest ... Ocutek® now makes them available ... the coveted Meisterbrief certificate, which ... qualified to become Ocutek instrument ...
... Centuries of German Craftsmanship have ... in the world. Ocutek now ... Only holders of the coveted ... eight-year apprenticeship, are qualified to ...
Medicine Products: